Simental-Mendía Luis E, Sahebkar Amirhossein, Rodríguez-Morán Martha, Guerrero-Romero Fernando
Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
Pharmacol Res. 2016 Sep;111:272-282. doi: 10.1016/j.phrs.2016.06.019. Epub 2016 Jun 18.
A systematic review and meta-analysis was conducted to evaluate the effect of oral magnesium supplementation on insulin sensitivity and glucose control in both diabetic and non-diabetic individuals. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched (from inception to November 25, 2015) to identify RCTs evaluating the effect of magnesium on insulin sensitivity and glucose control. A random-effects model and generic inverse variance method were used to compensate for the heterogeneity of studies. Publication bias, sensitivity analysis, and meta-regression assessments were conducted using standard methods. The impact of magnesium supplementation on plasma concentrations of glucose, glycated hemoglobin (HbA1c), insulin, and HOMA-IR index was assessed in 22, 14, 12 and 10 treatment arms, respectively. A significant effect of magnesium supplementation was observed on HOMA-IR index (WMD: -0.67, 95% CI: -1.20, -0.14, p=0.013) but not on plasma glucose (WMD: -0.20mmol/L, 95% CI: -0.45, 0.05, p=0.119), HbA1c (WMD: 0.018mmol/L, 95% CI: -0.10, 0.13, p=0.756), and insulin (WMD: -2.22mmol/L, 95% CI: -9.62, 5.17, p=0.556). A subgroup analysis comparing magnesium supplementation durations of <4 months versus ≥4 months, exhibited a significant difference for fasting glucose concentrations (p<0.001) and HOMA-IR (p=0.001) in favor of the latter subgroup. Magnesium supplementation for ≥4 months significantly improves the HOMA-IR index and fasting glucose, in both diabetic and non-diabetic subjects. The present findings suggest that magnesium may be a beneficial supplement in glucose metabolic disorders.
进行了一项系统评价和荟萃分析，以评估口服补充镁对糖尿病和非糖尿病个体胰岛素敏感性及血糖控制的影响。检索了PubMed-Medline、SCOPUS、Web of Science和谷歌学术数据库（从数据库建立至2015年11月25日），以识别评估镁对胰岛素敏感性及血糖控制影响的随机对照试验（RCT）。采用随机效应模型和通用逆方差法来弥补研究的异质性。使用标准方法进行发表偏倚、敏感性分析和荟萃回归评估。分别在22个、14个、12个和10个治疗组中评估了补充镁对血浆葡萄糖浓度、糖化血红蛋白（HbA1c）、胰岛素和稳态模型评估胰岛素抵抗（HOMA-IR）指数的影响。观察到补充镁对HOMA-IR指数有显著影响（加权均数差：-0.67，95%置信区间：-1.20，-0.14，p=0.013），但对血浆葡萄糖（加权均数差：-0.20mmol/L，95%置信区间：-0.45，0.05，p=0.119）、HbA1c（加权均数差：0.018mmol/L，95%置信区间：-0.10，0.13，p=0.756）和胰岛素（加权均数差：-2.22mmol/L，95%置信区间：-9.62，5.17，p=0.556）无显著影响。一项比较补充镁持续时间<4个月与≥4个月的亚组分析显示，空腹血糖浓度（p<0.001）和HOMA-IR（p=0.001）在≥4个月的亚组中存在显著差异，且该亚组更具优势。在糖尿病和非糖尿病受试者中，补充镁≥4个月可显著改善HOMA-IR指数和空腹血糖。目前的研究结果表明，镁可能是一种对糖代谢紊乱有益的补充剂。
